The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 8230115 |
16 |
Inhibitors of blood platelet cAMP phosphodiesterase. 4. Structural variation of the side-chain terminus of water-soluble 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
| 1336055 |
22 |
Novel cAMP PDE III inhibitors: 1,6-naphthyridin-2(1H)-ones. |
Sterling Winthrop Pharmaceuticals Research Division |
| 1732525 |
11 |
Heteroatom analogues of bemoradan: chemistry and cardiotonic activity of 1,4-benzothiazinylpyridazinones. |
R. W. Johnson Pharmaceutical Research Institute |
| 1321911 |
59 |
Inhibitors of blood platelet cAMP phosphodiesterase. 3. 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives with enhanced aqueous solubility. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
| 2153210 |
32 |
6-Benzoxazinylpyridazin-3-ones: potent, long-acting positive inotrope and peripheral vasodilator agents. |
R. W. Johnson Pharmaceutical Research Institute |
| 2913296 |
4 |
Cardiotonic agents. 1-Methyl-7-(4-pyridyl)-5,6,7,8-tetrahydro-3 (2H)-isoquinolinones and related compounds. Synthesis and activity. |
Mitsui Toatsu Chemicals |
| 2536438 |
10 |
Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for the treatment of congestive heart failure. |
Warner-Lambert |
| 3385731 |
12 |
Cardiotonic agents. Synthesis and inotropic activity of a series of isoquinolin-3-ol derivatives. |
Ortho Pharmaceutical |
| 2846839 |
24 |
Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazoline. |
Syntex Research |
| 3039135 |
16 |
Synthesis and cardiotonic activity of a series of substituted 4-alkyl-2(1H)-quinazolinones. |
TBA |
| 3027339 |
89 |
Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide (RS-82856). |
TBA |
| 3027338 |
20 |
Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostamide and anagrelide. |
TBA |
| 3656349 |
10 |
Cardiotonic agents. 6. Synthesis and inotropic activity of 2,4-dihydro-5-[4-(1H-imidazol-1-yl)phenyl]-3H-pyrazol-3-ones: ring-contracted analogues of imazodan (CI-914). |
Warner-Lambert/Parke-Davis Pharmaceutical Research |
| 3701782 |
6 |
Bipyridine cardiotonics: the three-dimensional structures of amrinone and milrinone. |
TBA |
| 3950907 |
6 |
Cardiotonic agents. 3. Synthesis and biological activity of novel 6-(substituted 1H-imidazol-4(5)-yl)-3(2H)-pyridazinones. |
TBA |
| 3783575 |
3 |
Cardiotonic agents. 4. Synthesis and biological evaluation of N-substituted 2,4,4a,5-tetrahydro-3H-indeno[1,2-c]pyridazin-3-ones: rigid structures derived from CI-930 and analogues. |
TBA |
| 11128646 |
69 |
Synthesis and biological evaluation of 2,5-dihydropyrazol. |
RhôNe-Poulenc Rorer |
| 10636238 |
71 |
Synthesis and structure-activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indoles: novel PDE4 inhibitors. |
Institut De Recherche Jouveinal-Parke Davis |
| 9871607 |
32 |
Phosphodiesterase inhibitory properties of losartan. Design and synthesis of new lead compounds. |
RhôNe-Poulenc Rorer |
| 27597413 |
58 |
Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings. |
Southern Medical University |
| 26881908 |
13 |
De Novo Design at the Edge of Chaos. |
Swiss Federal Institute Of Technology (Eth) |
| 26789933 |
100 |
Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases. |
Intra-Cellular Therapies |
| 26526739 |
35 |
Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships. |
Southern Medical University |
| 26430878 |
102 |
Synthesis of Fluorine-Containing Phosphodiesterase 10A (PDE10A) Inhibitors and the In Vivo Evaluation of F-18 Labeled PDE10A PET Tracers in Rodent and Nonhuman Primate. |
Washington University |
| 26319621 |
32 |
Design and discovery of 2-(4-(1H-tetrazol-5-yl)-1H-pyrazol-1-yl)-4-(4-phenyl)thiazole derivatives as cardiotonic agents via inhibition of PDE3. |
Daqing Oil Field General Hospital |
| 25592707 |
31 |
Synthesis and in vitro characterization of cinnoline and benzimidazole analogues as phosphodiesterase 10A inhibitors. |
Washington University |
| 26102506 |
40 |
Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115. |
Celgene |
| 25815146 |
29 |
Pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines as Selective, Brain Penetrant Phosphodiesterase 2 (PDE2) Inhibitors. |
Janssen Pharmaceutica |
| 25221665 |
33 |
Structure-Based Design of a Potent, Selective, and Brain Penetrating PDE2 Inhibitor with Demonstrated Target Engagement. |
Janssen Pharmaceutica |
| 9873708 |
16 |
N-arylrolipram derivatives as potent and selective PDE4 inhibitors. |
Novartis Horsham Research Center |
| 23260348 |
91 |
Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors. |
Janssen-Cilag |
| 20005117 |
24 |
Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors. |
Islamic Azad University |
| 18299198 |
73 |
CoMFA and HQSAR studies on 6,7-dimethoxy-4-pyrrolidylquinazoline derivatives as phosphodiesterase10A inhibitors. |
St. John'S University |
| 15887951 |
29 |
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. |
Monash University (Parkville Campus) |
| 15780616 |
9 |
Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
| 11405657 |
123 |
Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives. |
Tanabe Seiyaku |
| 10090791 |
77 |
Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives. |
Tanabe Seiyaku |
| 8388468 |
37 |
Cyclic nucleotide phosphodiesterase inhibition by imidazopyridines: analogues of sulmazole and isomazole as inhibitors of the cGMP specific phosphodiesterase. |
Smithkline Beecham Pharmaceuticals |
| 2822927 |
51 |
Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity. |
Warner-Lambert |
| 2985781 |
53 |
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. |
TBA |
| 12824030 |
67 |
1,7- and 2,7-naphthyridine derivatives as potent and highly specific PDE5 inhibitors. |
Tanabe Seiyaku |
| 11755362 |
24 |
Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: a potent and selective phosphodiesterase type 4D inhibitor. |
Novartis Pharma |
| 21955943 |
47 |
Investigation of the pyrazinones as PDE5 inhibitors: evaluation of regioisomeric projections into the solvent region. |
Pfizer |
| 21705115 |
37 |
Synthesis and in vitro evaluation of new analogues as inhibitors for phosphodiesterase 10A. |
Washington University |
| 21330134 |
4 |
Discovery of new inhibitor for PDE3 by virtual screening. |
Korea Research Institute Of Chemical Technology |
| 21189023 |
66 |
Synthesis and molecular modeling of novel tetrahydro-ß-carboline derivatives with phosphodiesterase 5 inhibitory and anticancer properties. |
German University In Cairo |
| 20196613 |
32 |
Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5). |
Pfizer |
| 19631533 |
126 |
Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one. |
Pfizer |
| | 71 |
Imidazotriazinone inhibitors of the Ca2+-calmodulin sensitive phosphodiesterase (PDE I) |
TBA |
| | 36 |
Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction |
TBA |
| 19339180 |
69 |
The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents. |
Pfizer |
| 16275071 |
26 |
A new chemical tool for exploring the physiological function of the PDE2 isozyme. |
Pfizer |
| 16263279 |
37 |
A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function. |
Pfizer |
| 16005625 |
162 |
Discovery of hydroxamic acid analogs as dual inhibitors of phosphodiesterase-1 and -5. |
Sumitomo Pharmaceuticals |
| 15149695 |
24 |
New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors. |
Pfizer |
| 15125967 |
30 |
Identification of purine inhibitors of phosphodiesterase 7 (PDE7). |
Bristol-Myers Squibb Pharmaceutical Research Institute |
| 15125945 |
6 |
PDE2 inhibition by the PI3 kinase inhibitor LY294002 and analogues. |
Monash University |
| 15080987 |
20 |
Synthesis and phosphodiesterase 5 inhibitory activity of new sildenafil analogues containing a phosphonate group in the 5(')-sulfonamide moiety of phenyl ring. |
Ewha Womans University |
| 15006407 |
15 |
Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
| 12182866 |
83 |
8-Aryl xanthines potent inhibitors of phosphodiesterase 5. |
Novartis Horsham Research Centre |
| 11958981 |
25 |
Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors. |
Bayer |
| 10197972 |
133 |
1-Arylnaphthalene lignan: a novel scaffold for type 5 phosphodiesterase inhibitor. |
Tanabe Seiyaku |
| 9990447 |
51 |
Synthesis and evaluation of potent and selective c-GMP phosphodiesterase inhibitors. |
Schering-Plough Research Institute |
| 9873643 |
75 |
Quinazolines: combined type 3 and 4 phosphodiesterase inhibitors. |
Novartis Pharma |
| 6620311 |
9 |
Optical resolution, absolute configuration, and activity of the enantiomers of proxyphylline. |
TBA |
| 6471063 |
10 |
Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure. |
TBA |
| 3585900 |
10 |
Cardiotonic agents. 5. 1,2-Dihydro-5-[4-(1H-imidazol-1-yl)phenyl]-6-methyl-2-oxo-3- pyridinecarbonitriles and related compounds. Synthesis and inotropic activity. |
TBA |
| 2822926 |
95 |
Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correlation with in vivo positive inotropic activi |
Warner-Lambert |
| 1654430 |
51 |
1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
| 1321910 |
237 |
Inhibitors of blood platelet cAMP phosphodiesterase. 2. Structure-activity relationships associated with 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones substituted with functionalized side chains. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
| 1311763 |
14 |
3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. |
Syntex Research |
Search and Browse
